Medicinehospital

Obinutuzumab

Obinutuzumab is an antibody infusion for chronic lymphocytic leukaemia, follicular lymphoma and lupus nephritis.

Clinical information

Common uses

chronic lymphocytic leukaemia
follicular lymphoma
lupus nephritis

Common side effects

infusion reactions
low white blood cells
upper airway infections
cough
constipation or diarrhoea

Cautions

boxed warning: can reactivate hepatitis B — screen before treatment
rare fatal brain infection (PML) reported
avoid live vaccines during treatment
patients monitored closely for infusion reactions

Interactions

live virus vaccines — avoid during treatment

Pregnancy: can deplete the baby's immune cells — avoid

Reference information, not medical advice — always follow your doctor or pharmacist. Source: DailyMed, dailymed.nlm.nih.gov, obinutuzumab (Gazyva) label, setid df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda (accessed 2026-08-16)

Approved brands & formulations1

Brand name	Dosage form	Strength	Importer	Category
Obinutuzumab	Parenteral ( Injection )	1000mg/40ml	MFDA designated importers with Pre Authorization approval before import	hospital